Christopher Green

Medicine & Life Sciences

1. SARS Virus 100%
2. Vaccines 69%
3. Coronavirus 60%
4. Vaccination 36%
5. Infections 35%
6. Clinical Protocols 33%
7. Respiratory Syncytial Virus Vaccines 29%
8. Respiratory Syncytial Viruses 27%
9. Pandemics 27%
10. Respiratory Tract Infections 25%
11. Safety 23%
12. Chad 23%
13. Neutralizing Antibodies 22%
14. Observational Studies 21%
15. Antibodies 18%
16. Clinical Trials, Phase I 16%
17. Severe Acute Respiratory Syndrome 16%
18. Cohort Studies 16%
19. Income 15%
20. Mortality 14%
21. Appointments and Schedules 14%
22. Artificial Respiration 13%
23. Prospective Studies 13%
24. Viruses 13%
25. Fecal Microbiota Transplantation 13%
26. Randomized Controlled Trials 12%
27. T-Lymphocytes 12%
28. England 12%
29. Pan troglodytes 12%
30. Antibody Formation 12%
31. Intensive Care Units 12%
32. Humoral Immunity 11%
33. Oxygen 11%
34. Coinfection 10%
35. Messenger RNA 10%
36. Adenoviridae 10%
37. Critical Illness 9%
38. Cellular Immunity 9%
39. Critical Care 9%
40. Equivalence Trials 8%
41. Pediatrics 8%
42. Viral Proteins 8%
43. Child 8%
44. Guidelines 8%
45. Therapeutics 8%
46. Meta-Analysis 8%
47. typhoid vaccine M01ZH09 7%
48. Genome-Wide Association Study 7%
49. Length of Stay 7%
50. Microbiota 7%